China joins US in brain implant race with clinical trial
BCI is an emerging technology to help restore functionality to people with paralysis, and Neuralink Corp, co-founded by Elon Musk, is at the forefront of this research. — Pixabay
China's first clinical trial of a technology that allows signals from the brain to control an external device has proved successful, making it only the second country after the US to reach this stage, according to the Global Times .
Chinese researchers used brain-computer interfaces, or BCI, a wireless invasive implant in a patient with tetraplegia in March, the English-language newspaper reported. Only a few weeks after the surgery, the patient was able to play racing games and chess on the computer using only the mind to control the electronic devices, it said, citing a statement from the Shanghai-based Center for Excellence in Brain Science and Intelligence Technology.
BCI is an emerging technology to help restore functionality to people with paralysis, and Neuralink Corp, co-founded by Elon Musk, is at the forefront of this research. The implant used in the Chinese trial is the world's smallest so far, with a diameter of 26 millimeters and thickness less than 6 millimeters, the Global Times said, adding that it's over 100 times more flexible than the one developed by Neuralink.
For the next stage, the team plans to enable the patient to operate a robotic arm using thoughts to perform more complex physical actions as such grasping and holding a cup. The center launched the trial in collaboration with Fudan University's Huashan Hospital.
Beijing has reported some experiments with implants by startup companies over the past months, but the clinical trial shows China is in a tight race with the US in developing this frontier technology. The center said the BCI system could get approval from the authorities, and be able to enter the market as early as 2028. – Bloomberg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
PingPong launches InvestXB In Luxembourg, Bringing Next- Generation Infrastructure To Alternative Investments
LUXEMBOURG, June 16, 2025 /PRNewswire/ — PingPong, a pioneer of cross-border embedded payment solutions with an established presence in Luxembourg since 2017, today launches InvestXB, a next-generation infrastructure solution for alternative investment managers, administrators and corporate solutions providers in Luxembourg. InvestXB delivers fast and compliant financial solutions designed for investment professionals launching and operating investment vehicles in Luxembourg, with the capability to support investors and assets globally. A Trusted And Robustly Regulated Partner, Designed For Global Investment Professionals In 2020, PingPong received approval from Luxembourg's financial regulator (CSSF) to upgrade from a Payment Institution (PI) licence to an Electronic Money Institution (EMI) licence. This EMI licence includes passporting rights, allowing PingPong to operate across all European Economic Area countries under CSSF supervision and regulation. Our ability to accelerate multi-currency account opening and onboard investment vehicles with global investors and assets, without compromising compliance, allows our team to navigate this complex landscape with tangible results. InvestXB can onboard investment vehicles with global investors and assets, including international Ultimate Beneficial Owners (UBOs), setting us apart from legacy providers. What's more, InvestXB is one of the few non-banks that enables global investment vehicles to open a multi-currency Luxembourg-based IBAN, which will accept incoming funds in 23 currencies, hold multiple currencies to match fund obligations and offer disbursements in over 200 countries and regions. 'InvestXB's global capabilities truly set us apart in the Luxembourg market. We enable investment vehicles to seamlessly match their fund obligations with access to 23 currencies for receiving, exchanging and sending funds, while facilitating disbursements and managing FX across over 200 countries and regions. Our ability to onboard investment vehicles with global investors and assets, including international UBOs based anywhere in the world, gives investment professionals the flexibility they need in today's interconnected investment landscape,' said Pawel Stosik, General Manager at PingPong Europe SA. Rapid Operational Efficiency, With 24-Hour Account Opening For fund managers, a key aspect of fundraising is speed. Yet traditional banks and legacy providers often take weeks, if not months, to approve and open accounts, causing critical delays for fund incorporation and operation. InvestXB offers a better solution, opening accounts within 24 hours, facilitating blocking certificates in minutes and providing the ability to deploy capital faster. What's more, InvestXB will allow global investment vehicles to open additional accounts on the same day. Where others see complexity, we see value, positioning InvestXB to lead innovation while adhering to the highest regulatory standards. Global Capabilities Backed By Local Expertise And Knowledge Speed matters at every touchpoint, from opening an account to day-to-day operations. Customer service is outdated and inefficient due to a lack of investment from legacy providers, meaning fund managers and administrators are waiting weeks for responses from account managers. Investment managers, fund administrators and corporate service providers deserve better support and infrastructure. InvestXB provides access to a dedicated team based in our central Luxembourg office. Our account managers are experts in Luxembourg fund compliance, regulation, structures, and management, ensuring seamless cross-jurisdictional support throughout the entire fund lifecycle. 'Missing the window to collect capital can mean losing investors altogether. With InvestXB, investment professionals can open accounts in hours, not weeks, while accessing dedicated support from our Luxembourg-based team of experts in fund compliance, regulation, and structures. Having reliable local knowledge and support throughout the fund lifecycle is critical for fund managers. It's like having a concierge service for all your fund administration needs, a next-generation solution designed specifically for sophisticated investors,' added Pawel Stosik. Explore how InvestXB can streamline your fund setup and operations here: About PingPong PingPong established a presence in Luxembourg in 2017 and, in 2020, received an EMI licence in Luxembourg with passporting rights across the EEA, all to solve the immense challenge of scaling enterprise businesses globally. Fast forward to today, and PingPong has become one of the world's leading global cross-border payments platforms, processing more than $250 billion USD. InvestXB by PingPong is a next-generation infrastructure solution for alternative investment managers, delivering fast, compliant, and scalable financial solutions designed for fund managers setting up and operating investment vehicles in Luxembourg. PingPong currently has 32 offices in 15 countries and 1,500 employees. Our international presence helps businesses solve complex payment needs in every major economy across all time zones. Logo – –
The Star
3 hours ago
- The Star
US pushes Vietnam to decouple from Chinese tech: Sources
Vietnam shipped US$33 billion of tech goods to the United States or 28% of the US-bound exports. - Vietnam News/ANN HANOI: The United States is pushing Vietnam in tariff talks to reduce the use of Chinese tech in devices that are assembled in the country before being exported to America, three people briefed on the matter said. Vietnam is home to large manufacturing operations of tech firms such as Apple and Samsung, which often rely on components made in China. Meta and Google also have contractors in Vietnam that produce goods such as virtual reality headsets and smartphones. The South-East Asian nation has been organising meetings with local businesses to boost the supply of Vietnamese parts, with firms showing willingness to cooperate but also warning they would need time and technology to do so, according to one person with knowledge of the discussions. The Trump administration has threatened Vietnam with crippling tariffs of 46% which could significantly limit access for Vietnam-made goods to their main market and upend the Communist-run country's export-oriented growth model. Vietnam has been asked "to reduce its dependency on Chinese high-tech," said one person familiar with the discussions. "That is part of the restructuring of supply chains and would in turn reduce US dependency on Chinese components," the person added. The ultimate objective is to speed up US decoupling from Chinese high-tech while increasing Vietnam's industrial capacity, a second person said, citing virtual reality devices as an example of Vietnam-assembled products that are too dependent on Chinese technology. All sources declined to be identified as the discussions were confidential. Reuters was not able to learn if the US has proposed numerical targets such as caps on Chinese content for "Made in Vietnam" goods or different tariff rates based on the amount of Chinese content. Apple, Samsung, Meta and Google did not reply to Reuters requests for comment. As the US-imposed deadline of July 8 nears before the tariffs take effect, the timing and scope of a possible deal remain unclear. All sources stressed that while the US has made broader requests for Vietnam to reduce its reliance on China, tackling the issue of Chinese high-tech content in exports was a key priority. Last year, China exported around US$44 billion of tech such as electronics components, computers and phones to Vietnam, about 30% of its total exports to the country. Vietnam shipped US$33 billion of tech goods to the United States or 28% of the US-bound exports. Both flows are on the rise this year, according to Vietnam's customs data. Vietnam's trade ministry did not reply to Reuters requests for comment. Separate sources have previously said that US demands were seen as "tough" and "difficult" by Vietnamese negotiators. The US also wants Vietnam to crack down on the practice of shipping Chinese goods to America with misleading "Made in Vietnam" labels that draw lower duties - which Vietnam is also trying to heed. The ministry said on Sunday that a third round of talks last week in Washington ended with progress, but critical issues remain unresolved. Vietnam's ruling Communist Party chief To Lam intends to meet US President Donald Trump in the United States, possibly in late June, officials with knowledge of the matter said. No date has been announced for the trip. The White House and Vietnam's foreign ministry did not respond to requests for comment on the possible visit. Local firms attending meetings organised by the trade ministry in recent weeks expressed a general willingness to adapt, but many warned that instant changes "would destroy business", according to one of the sources. Vietnam has been slowly developing an industrial ecosystem with local suppliers but it has a long way to go before it can match China's advanced supply chains and cheaper pricing, industry executives say. "Vietnam is about 15-20 years behind China in somewhat fully replicating its supply chain scale and sophistication, but it's catching up fast, especially in key sectors like textiles and electronics," said Carlo Chiandone, a Vietnam-based supply chain expert. Abrupt changes to existing practices may hurt Vietnam's delicate relationship with China, which is both a major investor in its South-East Asian neighbour and a source of security concerns. - Reuters
The Sun
3 hours ago
- The Sun
U.S. drugmakers boost licensing deals with Chinese biotechs
U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters. That increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters. "They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig Suvannavejh. The total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData. A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development risks. China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in March. Chinese companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and development. While small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. "Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony Ren. The growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America agenda. That has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from database. Roughly a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%. "I think it's only accelerating," Gleason said. The Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical sector. But one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs. "The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare group. In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is successful. Regeneron Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals. 'WAKEUP CALL' By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say. U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week. "We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told Reuters. What makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time." Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry. "It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
